An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE.

KOVAN B., ÖZKAN Z. G., DEMİR B., Tuncman D., IŞIK E. G., Simsek D., ...More

Cancer biotherapy & radiopharmaceuticals, vol.37, no.1, pp.17-22, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.1089/cbr.2021.0071
  • Journal Name: Cancer biotherapy & radiopharmaceuticals
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.17-22
  • Keywords: neuroendocrine tumors, dosimetry, Lutetium-177, MIRD, organ doses, RECEPTOR RADIONUCLIDE THERAPY, BONE-MARROW, DOSIMETRY, LU-177-DOTATATE, TOXICITY
  • Istanbul University Affiliated: Yes


Background: The aim of this study is to clarify the critical organs that limit treatment scheme and also evaluate the validity of currently used critical organ threshold values in neuroendocrine tumor (NET) patients, receiving peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (Lu-177)-DOTATATE. Thirty-six NET patients (ages 16-73 years) who received Lu-177-DOTATATE treatment were evaluated retrospectively in this study. Dosimetric calculations were made using medical internal radionuclide dose method. For calculation of organ doses, Internal Dose Assessment at Organ Level/Exponential Modelling 1.1 software program was used. Follow-up data were used to determine the organ failure.